CSF2 and neoplasm: T-VEC was optimized for immunotherapy by expressing the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) and can generate systemic antitumor immunity as evidenced by observations of tumor regression in non-injected lesions [4,7,8,9,10].